CD19 and diffuse large B-cell lymphoma: Concerning ACT using CARs, administration of CAR T cells recognizing CD19 are now approved for the treatment of acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) (29).